Insulin inhalation - Coremed
Alternative Names: AlveairLatest Information Update: 21 Jan 2022
At a glance
- Originator Coremed
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus in USA (Inhalation, Aerosol)
- 06 Jul 2005 Data presented at the 65th Scientific Sessions of the American Diabetes Association (ADA-2005) have been added to the pharmacokinetics section
- 29 Jun 2005 Coremed and Shanghai Fosun Pharmaceutical and Xuzhou Wanbang Biochemistry Pharmacy Factory have formed a joint venture partnership for clinical development and commercialisation of insulin inhalation Alveair™